![](/img/cover-not-exists.png)
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma
Romaguera, Jorge E., Wang, Michael, Feng, Lei, Fayad, Luis E., Hagemeister, Frederick, McLaughlin, Peter, Rodriguez, M. Alma, Fanale, Michelle, Orlowski, Robert, Kwak, Larry W., Neelapu, Sattva, Oki,Language:
english
Journal:
Cancer
DOI:
10.1002/cncr.31361
Date:
May, 2018
File:
PDF, 574 KB
english, 2018